SITE004-0243

SITE004 (DEU) › SITE004-0243

SITE004-0243

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-06-13

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-29 (study day 39); relationship: not assessed

severe assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 29); relationship: not assessed

moderate assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-05 (study day 15); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.